SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced on Oct. 5, 2026, that it submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market.
This development matters because it signals progress toward regulatory clearance in the United States for a surgical robotic system that aims to make robotic surgery more affordable and accessible. If cleared, the SSi Mantra could intensify competition in the U.S. surgical robotics market, which is currently dominated by a few major players. The system's cost-effective design may appeal to hospitals seeking to expand their robotic surgery programs without incurring the high costs associated with existing platforms.
The SSi Mantra is a modular, multi-arm system with advanced features such as 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient information display. It also includes a virtual real-time image of the robotic patient side arm carts and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.
Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. The company's vision is to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. For more information, visit ssinnovations.com or LinkedIn.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. TechMediaWire, a specialized communications platform with a focus on pioneering public and private companies driving the future of technology, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. For more information, please visit https://www.TechMediaWire.com. Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer.
